Option agreement includes three technologies and associated patent portfolios
This announcement marks the third strategic agreement for Coeptis this quarter, intended to strengthen its portfolio and complement its innovative cell therapy platforms.
WEXFORD, Pa., May 17, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has entered into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to treat a range of hematologic and solid tumors. Among the early cancer indications in development are preclinical programs targeting breast cancer and ovarian cancer. The terms of the contract are not disclosed.
The exclusive option agreement covers the intellectual property rights of three technologies jointly developed in the laboratories of Jason LohmuellerPh.D., assistant professor of immunology; Alexander Deiters, Ph.D., professor of chemistry; and Olivier Finn, Ph.D., Professor of Immunology: 1) mSA2 affinity-enhanced biotin-binding CAR, 2) universal self-labeling SynNotch and CAR for programmable antigen targeting, and 3) conditional control of CAR cells -T universal per stimulation- reactive adapters. In accordance with the option agreement, Coeptis paid the University of Pittsburgh a non-refundable royalty for the exclusive option to license the patent rights to each of the three technologies. Coeptis has up to October 29, 2022, to exercise the options and to pay the specified exercise consideration. The option agreement can be extended for an additional six months, subject to the agreement of both parties.
“2022 has been a year of transformation for Coeptis, and this exclusive option agreement with the University of Pittsburgh offers an unprecedented opportunity to license three breakthrough CAR-T technologies that we believe have the potential to deliver CAR-T therapies to treat both hematologic and solid tumors,” said Dave Mehalick, CEO of Coeptis Therapeutics. “We are delighted to have the opportunity to collaborate with the University of Pittsburgh to advance these innovative CAR-T technologies, which have the potential to be applied to a wide range of cancers currently underserved by conventional treatment options and first-generation CAR-T therapies, including breast cancer and of the ovary.
“CAR-T offers the potential to revolutionize cancer treatment; however, there remain gaps in current CAR-T therapies that we believe could allow the technology to be used with other types of cancer, including many solid tumors,” said Jason Lohmueller. “Our efforts at University of Pittsburgh involve three main opportunities: the creation of a universal CAR-T system that maintains high binding affinity, while providing better control of toxicity; develop technology that can target multiple antigens simultaneously; and allow conditional control of cellular receptors for systemic control over CAR-T cells. We welcome the opportunity to partner with Coeptis to advance these technologies.”
The option agreement with the University of Pittsburgh marks the third significant event for Coeptis this quarter and follows the recently announced definitive merger agreement with Bull Horn Holdings Corp. [“Bull Horn”] (Nasdaq: BHSE), a special purpose acquisition company (SPAC) expected to close in the third quarter of 2022. Additionally, in April, Coeptis entered into a strategic agreement with Statera Biopharma, Inc. which gives Coeptis the right to acquire, subject to the satisfaction of certain conditions, Statera’s Toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently in development for the treatment of acute irradiation.
About Coeptis Therapeutics, Inc.
Coeptis Therapeutics, Inc., together with its wholly owned subsidiary Coeptis Pharmaceuticals, Inc. (together “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by cell therapy technology (CD38-GEAR-NK) and in vitro diagnostics (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen- Bio and leading medical researchers from the Karolinska Institute. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through license agreements, license agreements and co-development relationships, as well as conclusion of strategic partnerships to extend its rights and product offerings, in particular those targeting cancer. Coeptis was founded in 2017 and is headquartered in Wexford, PA. For more information about Coeptis, visit https://coeptistx.com/.
About the University of Pittsburgh
A nonsectarian, coeducational, state-affiliated public research university founded in 1787, the University of Pittsburgh (pitt) is an invitation-only member of the prestigious Association of American Universities and internationally recognized as a leading center of learning and research in the arts, sciences, humanities, professions, and health sciences. Comprising a campus in Pittsburgh, home to 16 undergraduate, graduate, and professional schools, and four regional campuses in western Pennsylvania, Pitt offers nearly 500 distinct programs of study and confers more than 8,500 degrees annually. Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998 and is among the top 10 U.S. research universities nationally in terms of total federal obligations for science and science research and development. engineering. For more information, visit www.pitt.edu.
Caution Regarding Forward-Looking Statements
This press release and statements by our management made in connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements regarding our plans, objectives, goals, strategies, future events or performance, as well as underlying assumptions and other statements other than statements of historical fact. When we use words such as “may”, “will”, “intend”, “should”, “believe”, “expect”, “anticipate”, “plan”, “estimate” or similar expressions that do not relate solely to historical matters, we make forward-looking statements. Forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties that may affect actual results (including, without limitation (i) whether we will exercise the option with the University of Pittsburgh, or the benefits of the technology subject to such option and (ii) whether we will be able to complete our proposed merger with Bull Horn Holdings Corp., each as described herein) to differ materially and possibly substantially from our expectations discussed in the draft-view statements. All forward-looking statements are subject to significant risks and uncertainties, including, but not limited to, risks contained or to be contained in reports and other documents filed by us with the Securities and Exchange Commission. For these and other reasons, investors are cautioned not to place undue reliance on any forward-looking statements contained in this press release. Other factors are discussed in our filings or filings with the United States Securities and Exchange Commission, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances occurring after the date hereof, except as required by applicable laws, regulations or rules.
Bull Horn Holdings Corp.
University of Pittsburgh
Institute of Innovation
Show original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-enters-into-exclusive-option-agreement-with-university-of-pittsburgh-for-rights-to-car-t-technologies-designed- to-target-several-indications-of-cancer-including-hematological-and-solid-tumours-301548383.html
SOURCE Coeptis Therapeutics